

Product Datasheet

KPNA3 Antibody NB100-81650

Unit Size: 0.1 ml

Store at 4C. Do not freeze.

www.novusbio.com



technical@novusbio.com

Publications: 4

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB100-81650

Updated 10/23/2024 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB100-81650



NB100-81650**KPNA3 Antibody****Product Information**

Unit Size	0.1 ml
Concentration	0.2 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	TBS and 0.1% BSA
Target Molecular Weight	58 kDa

Product Description


Host	Rabbit
Gene ID	3839
Gene Symbol	KPNA3
Species	Human
Immunogen	The immunogen recognized by this antibody maps to a region between residue 1 and 50 of human karyopherin alpha 3 using the numbering given in entry NP_002258.2 (GeneID 3839).

Product Application Details


Applications	Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation
Recommended Dilutions	Western Blot 1:2000-1:10000, Immunohistochemistry 1:100 - 1:500, Immunoprecipitation 2-5 ug/mg lysate, Immunohistochemistry-Paraffin 1:100 - 1:500
Application Notes	Epitope retrieval with citrate buffer pH6.0 is recommended for FFPE tissue sections.

Images


Western Blot: KPNA3 Antibody [NB100-81650] - Association of NCBP3 and NCBP2 with NCBP1 and proteins involved in RNA processing. Western blot analysis of representative GFP-precipitated proteins identified by AP-MS analysis. Image collected and cropped by CiteAb from the following publication (<https://www.nature.com/articles/ncomms9192>), licensed under a CC-BY license.




Immunohistochemistry-Paraffin: KPNA3 Antibody [NB100-81650] - Human prostate carcinoma. Antibody used at a dilution of 1:200.




Western Blot: KPNA3 Antibody [NB100-81650] - Whole cell lysate from HeLa (5, 15 and 50 mcg for WB; 1 mg for IP, 20% of IP loaded) and 293T (T; 50 mcg) cells. NB100-81650 used for WB at 0.4 mcg/ml (A and B) and used for IP at 3 mcg/mg lysate.




Western Blot: KPNA3 Antibody [NB100-81650] - DZNep suppressed MPNST724 xenograft tumor initiation & growth in vivo. (A) MPNST724 xenograft tumor groups treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep 13 weeks after subcutaneous injection (n = 9 mice per group). (B) Growth curves of tumors treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep over a period of 13 weeks. Mean \pm SD values are shown; *p < 0.05, Student t test. (C) Western blot analyses of EZH2, KPNB1, & actin in tumor MPNST samples treated with vehicle only, 1 mg/kg DZNep, or 5 mg/kg DZNep. Image collected & cropped by CiteAb from the following publication (<http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: KPNA3 Antibody [NB100-81650] - DZNep inhibited EZH2/miR-30d/KPNB1 signaling in MPNST cells. (A) Western blot analyses of EZH2, cleaved PARP (cPARP), KPNB1, & GAPDH (loading control) in MPNST724 & S462 cells treated with DZNep at increasing concentrations for 48 hours. (B) qRT-PCR analyses of miR-30d expression in MPNST724 & S462 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean \pm SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that DZNep treatment increased miR-30d promoter activity in S462 cells. Mean \pm SD values are shown (n = 3); *p < 0.05; Student t test. (D) Luciferase reporter assay showed that DZNep treatment inhibited miR-30d target reporter activity in S462 cells. Mean \pm SD values are shown (n = 3); **p < 0.01, Student t test. (E) Luciferase reporter assay indicated that DZNep treatment inhibited wild-type (WT) KPNB1 3'UTR reporter activity but not mutant (MT) KPNB1 3'UTR reporter activity in S462 cells. Mean \pm SD values are shown (n = 3); *p < 0.05, Student t test. Image collected & cropped by CiteAb from the following publication (<http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: KPNA3 Antibody [NB100-81650] - EZH2-regulated miR-30a targeted KPNB1 in MPNST cells. (A) Putative miR-30a & miR-30d target site in the wild-type KPNB1 3'UTR region. (B) qRT-PCR analyses of miR-30a in MPNST724 & S462 cells transfected with a negative control or EZH2 siRNA. miR-30a expression was normalized to SNORD47. Data are shown as mean \pm SD (n = 3); *p < 0.05, Student t test. (C) qRT-PCR analyses of miR-30a in S462 & MPNST724 cells treated with DZNep for 96 hours. miR-30d expression was normalized to SNORD47. Mean \pm SD values are shown (n = 3); *p < 0.05, Student t test. (D) Western blot analyses of KPNB1 & actin in S462 & MPNST724 cells transfected with a negative control (Ctl) or miR-30a (30a) mimics. (E) Luciferase reporter assay showed that miR-30a inhibited wild-type (WT) KPNB1 3'UTR reporter activity but not mutant (MT) KPNB1 3'UTR reporter activity in S462 cells. Mean \pm SD values are shown (n = 3); *p < 0.05, Student t test. (F) qRT-PCR analyses of miR-30a expression in normal Schwann cells (NSC) & multiple MPNST cell lines (MPNST724, S462, STS26T, MPNST624, T265, & ST88-14). Image collected & cropped by CiteAb from the following publication (<http://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-015-0325-1>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Gebhardt A, Habjan M, Benda C et al. mRNA export through an additional cap-binding complex consisting of NCBP1 and NCBP3. *Nat Commun* 2015-09-18 [PMID: 26382858] (WB, Human)

Zhang P, Yang X, Ma X et al. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. *Mol Cancer* 2015-01-01 [PMID: 25890085] (IF/IHC)

Zhang P, Garnett J, Creighton CJ et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell survival and tumorigenesis. *J. Pathol.* 2014-02-01 [PMID: 24132643] (WB, IHC-P, Human)

Okazaki K, Nakayama N, Nariai Y et al. Nuclear localization signal in a cancer-related transcriptional regulator protein NAC1. *Carcinogenesis* 2012-10-01 [PMID: 22665369]



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB100-81650

NBL1-12371	KPNA3 Overexpression Lysate
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-81650

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

